Stockscreener 앱 받기
9.39
0.00%
0.00
시간 외 거래:
9.68
0.29
+3.09%
전일 마감가:
$9.39
열려 있는:
$9.46
하루 거래량:
248.12K
Relative Volume:
0.46
시가총액:
$482.05M
수익:
$57.94M
순이익/손실:
$-151.18M
주가수익비율:
-3.3397
EPS:
-2.8116
순현금흐름:
$-86.56M
1주 성능:
+5.74%
1개월 성능:
+7.31%
6개월 성능:
+4.68%
1년 성능:
+7.07%
1일 변동 폭
$9.19
$9.49
1주일 범위
$8.58
$9.52
52주 변동 폭
$7.73
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
명칭
Prothena Corp Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
9.39 | 463.57M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corp Plc 주식(PRTA)의 최신 뉴스
Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock - MarketBeat
Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones - Stock Traders Daily
HC Wainwright Issues Positive Estimate for Prothena Earnings - MarketBeat
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise - Sahm
Prothena Corporation PLC (PRTA) Stock News Today - TradingKey
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - tradingview.com
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Prothena: Q2 Earnings Snapshot - marketscreener.com
Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone - Stock Titan
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com
FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - stocktitan.net
Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corporation PLC expected to post a loss of 39 cents a shareEarnings Preview - tradingview.com
Technical Reactions to PRTA Trends in Macro Strategies - Stock Traders Daily
Prothena (NASDAQ:PRTA) Insider Anne Evans Kingston Sells 7,662 Shares of Stock - MarketBeat
Prothena Corp PLC (PRTA) Chief Strategy Officer Anne Kingston Se - GuruFocus
Prothena Q2 Results: Financial data release set for Aug 6 - scanx.trade
BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock - Stock Titan
Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV - TradingView
Rubric Capital Management LP Has $48.60 Million Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
PRTA|Prothena Corporation PLC|Price:8.720|Chg%:-0.030 - TradingKey
Prothena stock trades steady as Alzheimer portfolio advances and earnings show growing R&D investmen - Ad-hoc-news.de
Trading the Move, Not the Narrative: (PRTA) Edition - Stock Traders Daily
Michael John Isaacs Net Worth (2026) - GuruFocus
Prothena (PRTA) Price Target Increased by 37.50% to 16.83 - msn.com
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - Yahoo Finance
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens - ad-hoc-news.de
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Price to sales forward of Prothena Corporation plc – NASDAQ:PRTA - tradingview.com
PRTAProthena Corp Plc Options - Finviz
Price to sales forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Price to book forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to EBITDA forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corp. Plc – MUN:0PT - TradingView
Prothena Corp, Parkinson antibody program draws attention for the stock - ad-hoc-news.de
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA) - TradingView
Prothena Corp. Plc Actuals & Estimates (DUS:0PT) - TradingView
Prothena Corp. Plc Actuals & Estimates (SWB:0PT) - TradingView
PRTA Forecast — Price Target — Prediction for 2027 - TradingView
0PT Forecast — Price Target — Prediction for 2027 - TradingView
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit - Moomoo
Prothena Corp plc strategy in focus, shares watched against biotech peers - AD HOC NEWS
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prothena Corp Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prothena Corp Plc 주식 (PRTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 10% Owner |
Aug 07 '26 |
Buy |
8.62 |
34,000 |
293,053 |
790,000 |
| SCULLY WILLIAM P | 10% Owner |
Aug 07 '26 |
Buy |
8.62 |
3,500 |
30,167 |
83,500 |
| Kingston Anne Evans | Chief Strategy Officer |
Jul 29 '26 |
Sale |
8.47 |
7,662 |
64,919 |
55,782 |
| Isaacs Michael John | General Counsel & Company Sec. |
Jul 29 '26 |
Sale |
8.47 |
8,386 |
71,055 |
35,745 |
0.00%
3.22%
자본화:
|
볼륨(24시간):